Fresenius Medical Care increases investment in Humacyte, accompanies human acellular vessel developer’s stock market launch
WALTHAM, Mass., Aug. 30, 2021 /PRNewswire/ — Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, is investing an additional USD 25 million in the U.S. medical company Humacyte, Inc. In connection…
